Oral immunotherapy in severe cow’s milk allergic patients treated with omalizumab : Real life survey from a Spanish registry
Abstract Background Oral immunotherapy is a frequent treatment for the management of food allergies, but adverse events (AE) are common. This study assessed the outcome of cow's milk oral immunotherapy (MOIT) in severe cow`s milk–allergic patients treated with omalizumab in a real‐life setting. Methods OmaBASE was a national, multicenter, open, and observational registry that collected clinical, immunologic, and treatment from patients with food allergy receiving omalizumab. Results Data derived from 58 patients aged 10.3 years (IQR 6.3‐13.2) and median milk‐specific IgE 100 kU A/L at the start of omalizumab treatment. Most had experienced anaphylaxis by accidental exposures (70.7%) and had asthma (81.0%). Omalizumab in monotherapy induced tolerance to ≥6000 mg of cow's milk protein (CMP) to 34.8% of patients tested by oral food challenge. Omalizumab combined with MOIT conferred desensitization to ≥6000 mg of CMP to 83.0% of patients. Omalizumab withdrawal triggered more AE ( P = .013) and anaphylaxis ( P = .001) than no discontinuation. Anaphylaxis was observed in 36.4% of patients who discontinued omalizumab, and more in those with sudden (50.0%) rather than progressive (12.5%) discontinuation. At database closure, 40.5% of patients who had completed follow‐up tolerated CMP without omalizumab (7.2% 1500‐4500 mg; 33.3% ≥6000 mg). Conclusion Milk oral immunotherapy initiated under omalizumab allows the desensitization of subjects with severe cow's milk allergy even after omalizumab discontinuation. However, discontinuation of omalizumab can lead to severe AE and should be carefully monitored..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Pediatric Allergy and Immunology - 32(2021), 6, Seite 1287-1295 |
| Beteiligte Personen: |
Ibáñez‐Sandín, María Dolores [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
Copyright © 2021 John Wiley & Sons A/S |
|---|
| Umfang: |
9 |
|---|
| doi: |
10.1111/pai.13517 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY012016101 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY012016101 | ||
| 003 | DE-627 | ||
| 005 | 20230307233421.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230219s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/pai.13517 |2 doi | |
| 028 | 5 | 2 | |a PAI_PAI13517.xml |
| 035 | |a (DE-627)WLY012016101 | ||
| 035 | |a (WILEY)PAI13517 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.45 |2 bkl | ||
| 084 | |a 44.67 |2 bkl | ||
| 100 | 1 | |a Ibáñez‐Sandín, María Dolores |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oral immunotherapy in severe cow’s milk allergic patients treated with omalizumab |b Real life survey from a Spanish registry |
| 264 | 1 | |c 2021 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2021 John Wiley & Sons A/S | ||
| 520 | |a Abstract Background Oral immunotherapy is a frequent treatment for the management of food allergies, but adverse events (AE) are common. This study assessed the outcome of cow's milk oral immunotherapy (MOIT) in severe cow`s milk–allergic patients treated with omalizumab in a real‐life setting. Methods OmaBASE was a national, multicenter, open, and observational registry that collected clinical, immunologic, and treatment from patients with food allergy receiving omalizumab. Results Data derived from 58 patients aged 10.3 years (IQR 6.3‐13.2) and median milk‐specific IgE 100 kU A/L at the start of omalizumab treatment. Most had experienced anaphylaxis by accidental exposures (70.7%) and had asthma (81.0%). Omalizumab in monotherapy induced tolerance to ≥6000 mg of cow's milk protein (CMP) to 34.8% of patients tested by oral food challenge. Omalizumab combined with MOIT conferred desensitization to ≥6000 mg of CMP to 83.0% of patients. Omalizumab withdrawal triggered more AE ( P = .013) and anaphylaxis ( P = .001) than no discontinuation. Anaphylaxis was observed in 36.4% of patients who discontinued omalizumab, and more in those with sudden (50.0%) rather than progressive (12.5%) discontinuation. At database closure, 40.5% of patients who had completed follow‐up tolerated CMP without omalizumab (7.2% 1500‐4500 mg; 33.3% ≥6000 mg). Conclusion Milk oral immunotherapy initiated under omalizumab allows the desensitization of subjects with severe cow's milk allergy even after omalizumab discontinuation. However, discontinuation of omalizumab can lead to severe AE and should be carefully monitored. | ||
| 700 | 1 | |a Escudero, Carmelo |4 aut | |
| 700 | 1 | |a Candón Morillo, Rocío |4 aut | |
| 700 | 1 | |a Lasa, Eva M. |4 aut | |
| 700 | 1 | |a Marchán‐Martín, Eva |4 aut | |
| 700 | 1 | |a Sánchez‐García, Silvia |4 aut | |
| 700 | 1 | |a Terrados, Soledad |4 aut | |
| 700 | 1 | |a González Díaz, Carlos |4 aut | |
| 700 | 1 | |a Juste, Sonsoles |4 aut | |
| 700 | 1 | |a Martorell, Antonio |4 aut | |
| 700 | 1 | |a Gázquez García, Vanessa |4 aut | |
| 700 | 1 | |a Ramírez Jiménez, Antonio |4 aut | |
| 700 | 1 | |a Abellán, Ángel |4 aut | |
| 700 | 1 | |a Martos Calahorro, María D. |4 aut | |
| 700 | 1 | |a Tabar, Ana I. |4 aut | |
| 700 | 1 | |a Bartra, Joan |4 aut | |
| 700 | 1 | |a García Rodríguez, Rosa |4 aut | |
| 700 | 1 | |a Gómez Galán, Catalina |4 aut | |
| 700 | 1 | |a Martín‐Muñoz, María Flora |4 aut | |
| 700 | 1 | |a Meseguer Arce, José |4 aut | |
| 700 | 1 | |a Miralles, Juan C. |4 aut | |
| 700 | 1 | |a Montoro de Francisco, Ana M. |4 aut | |
| 700 | 1 | |a Poza Guedes, Paloma |4 aut | |
| 700 | 1 | |a Rodríguez del Río, Pablo |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric Allergy and Immunology |g 32(2021), 6, Seite 1287-1295 |w (DE-627)WLY01201172X |x 13993038 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:6 |g pages:1287-1295 |g extent:9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.45 |q ASE |
| 936 | b | k | |a 44.67 |q ASE |
| 951 | |a AR | ||
| 952 | |d 32 |j 2021 |e 6 |h 1287-1295 |g 9 | ||